Lupin announced the receipt of final FDA approval for a Abbreviated New Drug Application, signaling a potential entry into a valued therapeutic market. This regulatory clearance is poised to intensify generic competition with the existing brand, which is expected to significantly impact the product’s commercial prospects following its scheduled 2026 launch.